US Pat. No. 10,166,292

BLOCKING IL-9 SIGNALING IN CONJUNCTION WITH CHEMOTHERAPY TO TREAT CANCER

Mayo Foundation for Medic...

1. A method for treating a mammal having colon or breast cancer, wherein said method comprises administering a therapeutically effective amount of an inhibitor of IL-9 signaling alone to said mammal, wherein said inhibitor is an anti-IL-9 antibody, and wherein the progression of said colon or breast cancer or the number of colon or breast cancer cells within said mammal is reduced.
US Pat. No. 10,168,598

METHOD FOR SCANNING ALONG A CONTINUOUS SCANNING TRAJECTORY WITH A SCANNER SYSTEM

Femtonics Kft., Budapest...

1. A method for scanning along a continuous scanning trajectory with an electromagnetic beam, comprising the steps of:providing a first pair of acousto-optic deflectors comprising first and second acousto-optic deflectors for deflecting the electromagnetic beam in a x-z plane;
providing a second pair of acousto-optic deflectors comprising third and fourth acousto-optic deflectors for deflecting the electromagnetic beam in a y-z plane;
passing the electromagnetic beam through said first and second pairs of acousto-optic deflectors while providing time dependent acoustic frequency chirps wherein each individual frequency chirp changes with time continuously and non-linearly in the first, second, third and fourth deflectors so as to cause a focal spot of the electromagnetic beam to move continuously along the scanning trajectory.
US Pat. No. 10,165,781

COMPOSITIONS AND METHODS USEFUL FOR THE PREVENTION OF MALARIA AND DENGUE VIRUS TRANSMISSION

The Johns Hopkins Univers...

1. A method for controlling malaria and dengue virus transmission via mosquitoes comprising applying in an area where the mosquitoes are to be controlled a composition comprising mosquito nectar feed and Chromobacterium sp_Panamam (Csp_P).
US Pat. No. 10,167,318

D-ENANTIOMERIC PEPTIDES DERIVED FROM D3 AND USE THEREOF

FORSCHUNGSZENTRUM JUELICH...

1. A peptide comprising at least 50% D-enantiomeric amino acids and comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2 and homologs thereof having at least 83% sequence identity to SEQ ID NO: 2.
US Pat. No. 10,168,342

LIPID PROBES AND USES THEREOF

The Scripps Research Inst...

1. A high-throughput method of identifying lipid binding proteins as drug binding targets, comprising:a) harvesting a set of competitive lipid probe-protein complexes from a sample wherein the lipid probe comprises a lipid, a photoreactive group, and an affinity handle, and wherein the sample comprises a first cell solution and a second cell solution, and the second cell solution comprises a drug;
b) analyzing the set of lipid probe-protein complexes by a proteomic analysis means;
c) based on step b), determining i) a value for each of the lipid binding proteins from the set of lipid probe-protein complexes, and ii) a ligand binding site on each of the lipid binding proteins from the set of lipid probe-protein complexes; and
d) based on the value from c), generating a drug-lipid binding protein profile, wherein the drug-lipid binding protein profile is a profile that indicates an array of lipid binding proteins and respective ligand binding sites that interact with the drug, and wherein the drug-lipid binding protein profile is generated by the high-throughput method.
US Pat. No. 10,170,651

METAL-DOPED CU(IN,GA) (S,SE)2 NANOPARTICLES

Nanoco Technologies Ltd.,...

1. A process for preparing sodium-doped nanocrystals comprising:adding a sodium dialkyldithiocarbamate to a mixture of copper-, indium-, and gallium-containing reagents at the beginning of a synthesis reaction to form sodium-doped Cu(In,Ga)(S,Se)2 nanoparticles.
US Pat. No. 10,166,294

MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME

Serina Therapeutics, Inc....

1. A heterofunctional polyoxazoline derivative of the general structure:R1—{[N(COX)CH2CH2]o—[N(COR2)CH2—CH2)]n—[N(COY)CH2—CH2)]m}a—Z
wherein:
R1 is an initiating group;
R2 is independently selected for each repeating unit from an unsubstituted or substituted alkyl, an unsubstituted or substituted alkenyl, an unsubstituted or substituted aralkyl or an unsubstituted or substituted heterocyclylalkyl group;
X is a pendent moiety containing a first functional group;
Y is a pendent moiety containing a second functional group;
Z is a terminating nucleophile;
a is ran which indicates a random copolymer or block which indicates a block copolymer;
o and m are each an integer independently selected from 1-50;
n is an integer selected from 0-1000; and
wherein the first and second functional groups are each independently an alkyne, an amine, an oxyamine, an aldehyde, a ketone, an acetal, a ketal, an ester, a carboxylic acid, an activated carboxylic acid, an active carbonate, a chloroformate, an alcohol, an azide, a vinyl sulfone, a maleimide or orthopyridyl disulfide.
US Pat. No. 10,167,320

PURIFICATION OF VIRUS LIKE PARTICLES

Takeda Vaccines, Inc., C...

1. A solution comprising a purified population of human norovirus VLPs, wherein the norovirus VLPs comprise at least genogroup II VLPs, wherein said solution contains no more than about 80% residual contaminating protein relative to VLP, and wherein said solution is generated by a process comprising:generating or obtaining a cell lysate, culture supernatant, or filtrate containing the norovirus VLPs, wherein said norovirus VLPs comprise at least a first subpopulation with full length VP1 subunit and a second subpopulation with truncated VP1 subunit of the norovirus VLPs;
adjusting the pH of the lysate, supernatant or filtrate to a pH of less than about 5 to generate a pH-adjusted solution;
removing the second subpopulation with truncated VP1 subunit of norovirus VLPs from the pH-adjusted solution using a filtration process to generate a filtered solution, wherein the filtered solution substantially retains the first subpopulation with full length VP1 subunit of norovirus VLPs;
and
wherein the solution comprises full length VP1 subunit of norovirus VLPs and is substantially free of norovirus VLPs with the truncated VP1 subunit, wherein the solution contains less than about 10% truncated VP1 subunit.
US Pat. No. 10,167,576

METHOD OF PRODUCING FINE FIBER, AND FINE FIBER, NON-WOVEN FABRIC, AND FINE FIBROUS CELLULOSE

OJI Holdings Corporation,...

1. A method of producing a fine fiber, comprising:treating a cellulose raw material with an enzyme or an enzyme mixture; and
fibrillating the treated cellulose raw material,
wherein the cellulose raw material is a pulp for papermaking, a cotton pulp, a non-wood pulp, or cellulose isolated from sea squirts or seaweeds,
wherein said treating the cellulose raw material with the enzyme or the enzyme mixture comprises:
(a) treating the cellulose raw material with the enzyme, wherein the enzyme has both endo-glucanase activity and cellobiohydrolase activity, and wherein a ratio of the endo-glucanase activity relative to the cellobiohydrolase activity is 0.12 or greater; or
(b) treating the cellulose raw material with the enzyme mixture, wherein the enzyme mixture at least contains endo-glucanase and cellobiohydrolase, and wherein a ratio of the activity of the endo-glucanase relative to the activity of the cellobiohydrolase is 0.12 or greater.
US Pat. No. 10,165,784

METHOD FOR PRESERVING AND CONDITIONING BEEF BY COMBINING COMPOSITE ESSENTIAL OIL AND MODIFIED ATMOSPHERE PACKAGING

Jiangnan University, Wux...

1. A method for preserving and conditioning beef by combining composite essential oil and modified atmosphere, comprising:(1) cleaning and chopping picked fresh beef, dipping the fresh beef in a composite essential oil comprising a mass concentration of 0.8% clove essential oil, 0.8% cinnamon essential oil, and 0.8% illicium verum essential oil in 20% ethyl alcohol diluent for 30s and taking the beef out and draining slightly;
(2) placing the beef dipped in the step (1) into a modified atmosphere packaging box and fast precooling to reduce the internal temperature to 4-8° C.;
(3) vacuumizing the cooled modified atmosphere packaging box in the step (2), then inflating a mixed gas of O2, CO2 and N2 for modified atmosphere preservation with the inflating time of 3 s and pressure of 0.6 MPa;
(4) storing the beef subjected to the modified atmosphere packaging in the step (3) at 0-4° C.
US Pat. No. 10,167,321

CYTOMEGALOVIRUS ANTIGENS AND USES THEREOF

GLAXOSMITHKLINE BIOLOGICA...

1. A recombinant Human Cytomegalovirus (HCMV) gL protein, or a complex-forming fragment thereof, wherein said gL protein or fragment comprises a mutation at Protease Recognition Site residues 91-102 numbered according to SEQ ID NO: 1, wherein said mutation reduces protease cleavage at said Protease Recognition Site as compared to a control.
US Pat. No. 10,165,785

PROCESS FOR PRODUCING A COMPOSITION FOR INCREASING MUSCLE MASS

MYOS RENS TECHNOLOGY INC....

1. A process for producing a composition for increasing muscle mass, said process comprising:providing raw liquid egg yolk, raw liquid whole egg or raw liquid egg white originating from eggs,
diluting with a diluent and then concentrating the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a fraction containing the egg yolk membrane and/or the chalazae,
and subjecting the concentrated fraction to a step of preservation while maintaining the temperature at or below 38° C., wherein the step of preservation is selected from subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a high pressure treatment of at least 4500 bar for at least 1 min, from subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a pulsed electric field treatment of at least 5 kV/cm at a flow rate of 30 L/h, and from a combination of the high pressure treatment and the pulsed electric field treatment to provide a preserved liquid egg yolk, preserved liquid whole egg or preserved liquid egg white so that a composition for increasing muscle mass is produced.
US Pat. No. 10,166,297

ISOLATION OF NOVEL AAV'S AND USES THEREOF

University of Massachuset...

1. A method for delivering a transgene to a target tissue in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV) that transduces cells of the target tissue and a transgene, wherein the transgene is engineered to express an RNA transcript that comprises at least one binding site for a miRNA that is expressed in cells of an off-target tissue of the subject, wherein the at least one miRNA binding site is positioned in the 5?UTR or 3?UTR of the RNA transcript, wherein the transgene comprises a tissue-specific promoter selected from a thyroxin binding globulin (TBG) promoter, insulin promoter, glucagon promoter, somatostatin promoter, pancreatic polypeptide (PPY) promoter, synapsin-1 (Syn) promoter, creatine kinase (MCK) promoter, mammalian desmin (DES) promoter, ?-myosin heavy chain (?-MHC) promoter, and a cardiac Troponin T (cTnT) promoter, and wherein the rAAV comprises a capsid protein from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, or AAV12.
US Pat. No. 10,167,322

ENGINEERED ALBUMIN BINDING POLYPEPTIDE

AFFIBODY AB, Solna (SE)


wherein, independently from each other,
XA is selected from C and optionally functionalized K;
XB is selected from C and optionally functionalized K;
and
X5 is selected from F and Y;
X8 is selected from D, K, N, R and S;
X9 is selected from F, I, L, M, V and Y;
X11 is selected from D, E, N and S;
X12 is selected from K, N and R;
X14 is selected from K and R;
X20 is selected from D, E, H, K, N, Q, R and S;
X23 is selected from I, K and T;
X24 is selected from A, D, E, G, H, L, S and T;
X25 is selected from A, D, E and H;
X28 is selected from A and K;
X29 is selected from A, E and S; and
X31 is P or is absent; and
wherein the amino acid sequence optionally contains an intramolecular crosslink.
US Pat. No. 10,167,323

NUCLEIC ACID MOLECULES ENCODING INSECTICIDAL PROTEINS

Syngenta Participations A...

1. A nucleic acid molecule comprising a nucleotide sequence that encodes an engineered Cry1Ba (eCry1Ba) insecticidal protein comprising a mutation at a position corresponding to amino acids 2 and 150; or amino acids 2, 150 and 178; or amino acids 2, 150 and 189; or amino acids 2, 150 and 199, of SEQ ID NO: 5, wherein the amino acid corresponding to position 2 is any amino acid and (a) the amino acid corresponding to position 150 is Lys; or (b) the amino acid corresponding to position 150 is Lys and the amino acid corresponding to position 178 is Ser; or (c) the amino acid corresponding to position 150 is Lys and the amino acid corresponding to position 189 is Ser; or (d) the amino acid corresponding to position 150 is Lys and the amino acid corresponding to position 199 is Lys, and wherein said protein has improved solubility or insecticidal activity against at least European corn borer (Ostrinia nubilalis) when compared to a native or wild-type Cry1Ba protein, and wherein optionally the nucleotide sequence is optimized for expression in a transgenic host cell.
US Pat. No. 10,166,299

AAV MEDIATED AQUAPORIN GENE TRANSFER TO TREAT SJOGREN'S SYNDROME

THE UNITED STATES OF AMER...

1. A method to treat Sjögren's syndrome-associated xerostomia or xeropthalmia in a subject, comprising administering to the salivary gland or the lachrymal gland of the subject, an AAV vector that encodes an aquaporin-1 (AQP-1) protein.
US Pat. No. 10,167,324

PESTICIDAL GENES AND METHODS OF USE

AgBiome, Inc., Research ...

1. A recombinant polypeptide, comprising(a) a polypeptide comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 244, wherein said polypeptide of (a) has pesticidal activity and further comprises a heterologous amino acid sequence chemically linked to said polypeptide of (a); or,
(b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 244, wherein said polypeptide of (b) further comprises a heterologous amino acid sequence chemically linked to said polypeptide of (b).
US Pat. No. 10,165,788

METHODS AND COMPOSITIONS FOR IMPROVED DIGESTION OF MILK OLIGOSACCHARIDES

THE REGENTS OF THE UNIVER...

1. A method for promoting growth of beneficial gut bacteria in an individual having fucosylated oligosaccharides in the gut, comprising administering to the individual a composition comprising the beneficial gut bacteria, wherein the beneficial gut bacteria express a GH-29 family alpha-fucosidase and a GH-95 family alpha-fucosidase, wherein the beneficial gut bacteria are selected from B. adolescentis, B. catenulatum, B. pseudocatenulatum, B. dentium, and B. breve, thereby promoting growth of beneficial gut bacteria in the individual.
US Pat. No. 10,166,300

TRIPARTITE CANCER THERANOSTIC NUCLEIC ACID CONSTRUCTS

Virginia Commonwealth Uni...

1. A composition comprising a population of ultrasound targeted microbubbles, wherein the microbubbles comprise a lipid layer that stably binds a tripartite nucleic acid construct, and wherein the tripartite nucleic acid construct comprises a first promoter operably linked to at least one gene required for viral replication, a second promoter operably linked to a reporter gene , and a third promoter operably linked to a therapeutic gene, wherein the first promoter and the second promoter are each cancer-selective, and wherein the second promoter is SEQ. ID. NO. 15.
US Pat. No. 10,167,325

PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME

Human Matrix Sciences, LL...

1. A synthetic acetylated peptide comprising a sequence of IGVAPG (SEQ ID NO: 13), wherein acetylation is at N-terminus.
US Pat. No. 10,166,302

LABELING COMPOSITION FOR CANCER LESION

NATIONAL CANCER CENTER, ...

1. A method for providing information about a size and a site of a cancer lesion, the method comprising:(a) adding a radioactive isotope to a thiol macroaggregated albumin (MAA) to obtain a complex in which the thiol MAA binds to the radioactive isotope;
(b) adding at least one pigment for staining living tissues to the complex in (a);
(c) mixing the complex in (b) with a first mixture comprising thrombine and aprotinin and a second mixture comprising fibrinogen and CaCl2 to obtain the complex entangled in a fibrin;
(d) administering directly to a cancer tissue to be removed in a subject the complex obtained from (c); and
(e) identifying a size and a site of the cancer lesion through a signal selected from the group consisting of a color, a near-infrared fluorescence, a radioactivity, and a combination of two or more thereof, from the cancer tissue in real time during cancer-removing surgery.
US Pat. No. 10,167,327

THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES

BRISTOL-MYERS SQUIBB COMP...

1. A method of decreasing or inhibiting fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having at least 96% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.
US Pat. No. 10,165,791

USE OF RUBUSOSIDE FOR REDUCING OR SUPPRESSING CERTAIN UNPLEASANT TASTE IMPRESSIONS

Symrise AG, Holzminden (...

1. A method for masking the sour and/or astringent taste of a substance selected from the group consisting of quercitrin, gallic or ellagic acid esters of carbohydrates, pentagalloylglucose, galloylated catechins, galloylated epicatechins, proanthocyanidins, procyanidins, thearubigenin, and mixtures thereof, wherein the method is consisting of:adding to said substance, an amount of rubusoside that does not bring about a sweet taste impression that is greater than a sweet taste impression of a 1.5 wt. % aqueous sucrose solution, thereby masking sour and/or astringent taste of the substance.
US Pat. No. 10,166,303

RADIO-IMAGING AND RADIO-THERAPY OF CANCER USING ANTIBODIES TO HAAH

Panacea Pharmaceutical In...

1. A method for killing cancer cells, comprising the steps of:conjugating a radioisotope to a PAN-622 antibody, an antibody which binds to human aspartyl (asparaginyl) ß-hydroxylase (HAAH), to form a radiolabeled PAN-622 antibody and
contacting cancer cells with the radiolabeled PAN-622 antibody in an amount sufficient to kill the cancer cells, wherein the radiolabeled PAN-622 antibody binds to HAAH, thereby killing the cancer cells.
US Pat. No. 10,167,328

METHODS FOR CANCER THERAPY USING MUTANT LIGHT MOLECULES WITH INCREASED AFFINITY TO RECEPTORS

The University of Chicago...

1. A method of reducing the growth of primary tumor or cancer metastasis, the method comprising: (a) administering a pharmaceutical composition comprising a mutant human LIGHT molecule comprising an amino acid sequence selected from the group consisting of SEQ ID Nos: 3, 4, 5, and 20, wherein the composition is sufficient to stimulate of cytotoxic T lymphocytes against tumor cells.
US Pat. No. 10,166,304

ANTIBODY FRAGMENTS FOR DETECTING CANCER AND METHODS OF USE

Regents of the University...

1. An immune reagent comprising a first scFv antibody fragment that specifically binds to membrane protein HSPG2 (Perlecan), wherein the first scFv antibody fragment is Clone-6 (SEQ ID NO:2).
US Pat. No. 10,167,329

STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES

Novartis AG, Basel (CH)

1. A polypeptide comprising a human IGF-1 protein variant of SEQ ID NO: 1 wherein the amino acid glycine at position 42 is mutated to serine.
US Pat. No. 10,167,330

MODIFIED RECOMBINANT VARIABLE LYMPHOCYTE RECEPTORS (VLR)

Emory University, Atlant...

1. A recombinant polypeptide comprising an amino acid sequence XLXLXXNKLQTIAKGTFSPLRAIQXMXLXX (SEQ ID NO: 38) wherein X at each position is individually and independently any amino acid provided that the polypeptide does not contain at least one of the following wild-type Slit2-D2 sequences selected from LLSLYD (SEQ ID NO: 16), and TMHLAQ (SEQ ID NO: 17).
US Pat. No. 10,168,611

MASK WITH MULTILAYER STRUCTURE AND MANUFACTURING METHOD BY USING THE SAME

TAIWAN SEMICONDUCTOR MANU...

1. A structure, comprising:a first layer;
a second layer disposed over the first layer;
a third layer disposed over the second layer; and
a fourth layer disposed over the third layer;
wherein:
the first layer, the second layer, the third layer, and the fourth layer are layers of a reflective structure of a lithography mask;
the first layer and the second layer combined have a first thickness;
the third layer and the fourth layer combined have a second thickness that is different from the first thickness;
the first layer and the third layer have a first material composition; and
the second layer and the fourth layer have a second material composition different from the first material composition.
US Pat. No. 10,167,332

POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS

The Rockefeller Universit...

1. A modified IVIG composition prepared from an unmodified IVIG composition, wherein the modified IVIG composition has (i) increased anti-inflammatory activity as compared to the unmodified IVIG composition, and (ii) a higher content of ?2,6 linked sialic acid in the N-linked glycans of Fc regions than the unmodified IVIG composition.
US Pat. No. 10,168,613

MASK BLANK SUBSTRATE, MASK BLANK, TRANSFER MASK, AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Shinju...

1. A mask blank substrate for use in manufacturing a mask blank provided with a thin film for forming a transfer pattern on one of a pair of opposing principal surfaces of a transparent substrate,wherein the principal surface to which the thin film is provided has a surface shape of which, in a case where a shape fitting on a virtual reference surface is carried out and difference data between the principal surface and the virtual reference surface is obtained in a calculation region within an inner side of a circle of 90 mm diameter based on a center of a substrate, a difference between a maximum height and a minimum height within the calculation region of the difference data is ?/10 or less, provided that an exposure wavelength used for transfer is ?, and
wherein the virtual reference surface has a shape defined by a Zernike polynomial expressed by a polar coordinate system, and includes one or more terms in which an order of a variable related to a radius is a second order.
US Pat. No. 10,167,334

TREATMENT OF CANCER USING ANTI-TGF-BETA AND PD-1 ANTIBODIES

XOMA TECHNOLOGY LTD., Be...

1. A method for treating cancer or reducing the recurrence of cancer comprising administering to a subject having cancer or who has had cancer, in therapeutically effective amounts, an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of Programmed cell death protein 1 (PD-1), wherein the PD-1 inhibitor is an anti-PD-1 antibody; andwherein the TGF? inhibitor is an antibody that binds TGF? comprising:
a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 19;
b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 20;
c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 21;
d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 22;
e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 23; and
f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 24.
US Pat. No. 10,167,335

IL-1? NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Agency for Science, Techn...

1. An isolated IL-1? specific antigen binding protein comprising one or more binding units selected from the group consisting of the following binding units:(i) a binding unit LI comprising Kabat residues 24-33 of SEQ ID NO: 17;
(ii) a binding unit L2 comprising Kabat residues 49-55 of SEQ ID NO: 17;
(iii) a binding unit L3 comprising Kabat residues 88-96 of SEQ ID NO: 17, or a variant thereof which contains up to five conservative amino acid substitutions in the binding unit L3;
(iv) a binding unit HI comprising Kabat residues 31-35 of SEQ ID NO: 14;
(v) a binding unit H2 comprising Kabat residues 50-65 of SEQ ID NO: 14; and
(vi) a binding unit H3 comprising Kabat residues 98-108 of SEQ ID NO: 14.
US Pat. No. 10,167,336

METHODS AND MATERIALS FOR TREATING CANCER

Mayo Foundation for Medic...

1. A method for exerting anti-cancer effects in a mammal having cancer, wherein said method comprises:(a) identifying said mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells within a T cell-containing sample; relative to a reference level of PD-1+/CD11ahigh CD8 T cells in mammals without cancer; and
(b) administering a PD-1 inhibitor to said mammal under conditions wherein naturally occurring tumor-reactive CD8 CTLs within a PD-1+/CD11ahigh CD8 T cell population of said mammal exert said anti-cancer effects against said cancer.
US Pat. No. 10,167,592

COMPOSITION FOR FIBER ADHESION AND FABRICS USING THE SAME

DOMAC LLC., Sejong (KR)

5. An article comprising a fabric manufactured by weaving a coated yarn comprising a yarn selected from polyolefin fiber, polyester fiber, nylon fiber, polyvinyl chloride fiber, polyurethane fiber, glass fiber or carbon fiber; and a coating layer, which comprises a fiber adhesion composition, the fiber adhesion composition comprising a thermoplastic resin, a titanium dioxide, a flame retardant, an ultraviolet absorber, and a heat stabilizer, wherein the fabric has a solar reflectance of 70% or more, a visible light reflectance of 80% or more, a solar transmittance of 15% or less, a visible light transmittance of 10% or less and a UV transmittance of 5% or less, wherein the article is a blind or light-shielding film.
US Pat. No. 10,167,593

APPARATUS AND METHOD FOR APPLYING COLORS AND PERFORMANCE CHEMICALS ON CARPET YARNS

INVISTA NORTH AMERICA S.A...

1. A process for continuously applying a treatment to a single or twisted BCF yarn comprising:a. providing a single or twisted BCF (bulked continuous filament) yarn;
b. winding said yarn on a take up reel;
c. providing at least one rotating roll including a plurality of wicks for providing a dye treatment;
d. contacting said wicks with said dye treatment;
e. contacting said BCF yarn to apply the dye with said wicks to the BCF yarn while in motion prior to winding said yarn on said take up reel;
f. providing one or more applicators for one or more performance enhancing compositions after said at least one rotating roll;
g. applying the performance enhancing composition to said dyed BCF yarn while still in motion and without steam fixation and rinsing of said dyed BCF yarn prior to winding said yarn on said take up reel; and
h. heat setting said dyed and performance enhancing treated BCF yarn prior to winding said yarn on said take up reel,
wherein said yarn exhibits at least equivalent dyeing and enhancing composition performance to processes involving steam and rinsing between dyeing and application of performance enhancing compositions.
US Pat. No. 10,167,338

METHOD OF TREATING CANCER USING IL2R BETA/COMMON GAMMA CHAIN ANTIBODIES

AGENCY FOR SCIENCE, TECHN...


US Pat. No. 10,166,314

REGENERATIVE PROSTHESES AS ALTERNATIVES TO DONOR CORNEAS FOR TRANSPLANTATION

UAB Ferentis, Vilnius (L...

1. A corneal implant having a first surface and a second surface, the corneal implant comprising:a matrix part containing a matrix material including a hydrogel of at least one first polymer and at least one second polymer, the first polymer including collagen or collagen mimetic peptide (CMP) provided with methacrylate or acrylate functional groups, the second polymer including a synthetic or a natural polymer having functional groups selected from thiol, acrylate or methacrylate, and the first and second polymers are cross-linked via said functional groups; and
a core part in a central part of the matrix material, the core part including a core material of an interpenetrating network (IPN), the IPN including polymerized olefinic monomers, UV polymerizable monomers or a mixture thereof and the hydrogel of the matrix material, the core material exposed at the first surface and at the second surface, the core part being transparent such that the core part has a light transmission of at least 80% within a wavelength range of 400 nm to 700 nm, the core part being anti-fouling, the core part configured to block or hinder cell migration and vessel ingrowth.
US Pat. No. 10,167,339

ANTAGONISTIC ANTI-OX40L ANTIBODIES AND METHODS OF THEIR USE

Baylor Research Institute...

1. A method for treating an autoimmune disease, inflammation, and/or inflammation associated with an autoimmune disease, wherein the disease or inflammation is due, at least in part, to pathogenic Tfh cell responses, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an OX40L inhibitor wherein the OX40L inhibitor comprises an OX40L antibody or OX40L antigen-binding fragment comprising one of:a) a heavy chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7 and a light chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14;
b) a heavy chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21 and a light chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28; or
c) a heavy chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35 and a light chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42.
US Pat. No. 10,166,315

CHITOSAN-ENHANCED ELECTROSPUN FIBER COMPOSITIONS

NANOFIBER SOLUTIONS, INC....

1. A composition comprising:a plurality of synthetic polymeric electrospun fiber fragments; and
an aqueous carrier medium comprising an effective amount of chitosan;
wherein the plurality of synthetic polymeric electrospun fiber fragments are present in an amount from about 1 fragment per mm3 to about 100,000 fragments per mm3; and
wherein the effective amount of chitosan to the aqueous carrier medium is from about 0.0001 wt % to about 5 wt %.
US Pat. No. 10,167,340

ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY

Health Research, Inc., B...

1. An isolated monoclonal antibody that specifically binds to survivin comprising a heavy chain variable region and light chain variable region, wherein,a) the heavy chain variable region comprises a VH CDR1 comprising the sequence of SEQ ID NO: 7, a VH CDR2 comprising the sequence of SEQ ID NO: 8, and a VH CDR3 comprising the sequence of SEQ ID NO: 9, and the light chain variable region comprises a VL CDR1 comprising the sequence of SEQ ID NO: 10, a VL CDR2 comprising the sequence of SEQ ID NO: 11, and a VL CDR3 comprising the sequence of SEQ ID NO: 12; or
b) the heavy chain variable region comprises a VH CDR1 comprising the sequence of SEQ ID NO:13, a VH CDR2 comprising the sequence of SEQ ID NO:14, and a VH CDR3 comprising the sequence of SEQ ID NO:15, and the light chain variable region comprises a VL CDR1 comprising the sequence of SEQ ID NO:16, a VL CDR2 comprising the sequence of SEQ ID NO:17, and a VL CDR3 comprising the sequence of SEQ ID NO:18.
US Pat. No. 10,167,341

HIGH AFFINITY ANTI-GD2 ANTIBODIES

Memorial Sloan Kettering ...

1. A high affinity anti-GD2 antibody or antigen-binding fragment thereof whose structure is characterized by a feature which reduces immunogenicity and increases affinity to GD2 as compared with an appropriate reference anti-GD2 antibody,wherein the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences as set forth in any one of SEQ ID NOs: 11-16 and 19, 21-25, and
wherein the feature is selected from the group consisting of:
a light chain D32H mutation as numbered according to Kabat;
a light chain E1K mutation as numbered according to Kabat; and combinations thereof.
US Pat. No. 10,167,342

PRODUCTION OF HERSINTUZUMAB: A NEW HUMANIZED ANTIBODY AGAINST HER2 FOR CANCER TREATMENT

1. A humanized monoclonal anti-HER2 antibody for treating cancer, comprising:CDR-H1 comprising amino acid residues of 31-35 of SEQ ID NO: 1;
CDR-H2 comprising amino acid residues of 50-65 of SEQ ID NO: 1;
CDR-H3 comprising amino acid residues of 98-105 of SEQ ID NO: 1;
CDR-L1 comprising amino acid residues of 24-34 of SEQ ID NO: 5;
CDR-L2 comprising amino acid residues of 50-56 of SEQ ID NO: 5; and
CDR-L3 comprising amino acid residues of 89-97 of SEQ ID NO: 5.
US Pat. No. 10,167,343

ANTIBODIES AGAINST CD73

BRISTOL-MYERS SQUIBB COMP...

1. An isolated nucleic acid molecule encoding the heavy and light chains of an antibody which binds to human CD73, wherein the heavy and light chains respectively comprise:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 5, 6, and 7, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 9, 10, and 11, respectively;
(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 5, 6, and 7, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 13, 14, and 15, respectively;
(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 21, 22, and 23, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 25, 26, and 27, respectively;
(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 29, 30, and 31, respectively;
(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 37, 38, and 39, respectively;
(g) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 41, 42, and 43, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 46, and 47, respectively;
(h) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 41, 42, and 43, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;
(i) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 53, 54, and 55, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 57, 58, and 59, respectively;
(j) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 61, 62, and 63, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 66, and 67, respectively;
(k) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 69, 70, and 71, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 73, 74, and 75, respectively;
(l) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 69, 70, and 71, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 77, 78, and 79, respectively;
(m) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 81, 82, and 83, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 85, 86, and 87, respectively; or
(n) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 89, 90, and 91, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 93, 94, and 95, respectively.
US Pat. No. 10,167,344

MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE

Regeneron Pharmaceuticals...

1. A method for making an antibody comprising:expressing in a single cell:
(a) a first nucleic acid sequence that encodes a first immunoglobulin heavy chain, the first nucleic acid sequence comprising a first human immunoglobulin heavy chain variable region sequence operably linked to a human immunoglobulin heavy chain constant region sequence, wherein the first human immunoglobulin heavy chain variable region sequence is identified from a B cell of a first mouse, and wherein the first mouse has been immunized with a first antigen of interest including a first epitope, and the first mouse comprises in its germline genome:
(i) exactly two unrearranged human immunoglobulin V? gene segments and five unrearranged human immunoglobulin J? gene segments operably linked to a mouse immunoglobulin light chain constant region sequence at the endogenous kappa light chain loci of the mouse, wherein the two unrearranged human immunoglobulin V? gene segments are a human V?1-39 gene segment and a human V?3-20 gene segment; and
(ii) one or more unrearranged human immunoglobulin VH gene segments, one or more unrearranged human immunoglobulin DH gene segments, and one or more unrearranged human immunoglobulin JH gene segments operably linked to a mouse immunoglobulin heavy chain constant region sequence at the endogenous heavy chain loci of the mouse;
wherein the unrearranged human heavy chain and kappa light chain immunoglobulin gene segments of the first mouse are capable of rearranging and encoding human immunoglobulin variable domains of an antibody, wherein the first mouse does not comprise an endogenous immunoglobulin V? gene segment that is capable of rearranging to form an immunoglobulin light chain variable region sequence, and wherein the first human immunoglobulin heavy chain variable region sequence encodes a first human immunoglobulin heavy chain variable domain that recognizes the first epitope; and
(b) a second nucleic acid sequence that encodes an immunoglobulin light chain, the second nucleic acid sequence comprising a human immunoglobulin kappa light chain variable region sequence fused with a human immunoglobulin light chain constant region sequence, wherein the human immunoglobulin kappa light chain variable region sequence comprises a human V?1-39 gene segment, a human V?3-20 gene segment, or a somatically hypermutated version thereof;
maintaining the cell under conditions sufficient to express a fully human antibody; and
isolating the antibody.
US Pat. No. 10,167,345

ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS

1. A nucleic acid molecule encoding for an antigen binding format comprising:a first fusion protein wherein a CH1 constant domain of an antibody is fused i) by its N-terminal end to a C-terminal end of a first single domain antibody and ii) by its C-terminal end to an N-terminal end of a second single domain antibody, wherein the C-terminal end of the CH1 constant domain includes DKT which is fused directly to the N-terminal end of the second single domain antibody, and
a second fusion protein wherein a CL constant domain of an antibody is fused by its N-terminal end to a C-terminal end of a third single domain antibody, wherein said first, second and third single domain antibody may be the same or different, and wherein said CH1 constant domain and said CL constant domain are linked via a disulfide bond.
US Pat. No. 10,168,627

EXPOSURE APPARATUS AND METHOD FOR CLEANING THE SAME

SAMSUNG ELECTRONICS CO., ...

1. A method for cleaning an exposure apparatus, the method comprising:generating light from a light source system;
controlling and patterning the generated light by a reflection member of a chamber of an optical system;
transmitting the patterned light to a substrate system to perform an exposure process on a substrate;
closing a first on-off valve disposed between the chamber and the substrate system to seal the chamber during or after the exposure process; and
during or after the exposure process, supplying a cleaning gas into the chamber to perform a cleaning process to the inside of the chamber,
wherein particles in the chamber are exhausted to the substrate through an exhaust line extending from the chamber while the cleaning process is performed.
US Pat. No. 10,167,346

COMPOSITIONS AND METHODS FOR MAKING ALPHA-(1,2)-BRANCHED ALPHA-(1,6) OLIGODEXTRANS

1. A composition comprising an alpha-(1,2)-branched alpha-(1,6) oligodextran having alpha-(1,2)-osidic side chains, wherein said oligodextran comprises a backbone comprising alpha-D-glucopyranosyl units linked by alpha-(1,6)-linkages, wherein said alpha-(1,2)-osidic side chains are randomly distributed over the backbone, wherein said backbone has an average molecular weight between about 0.5 kDa and 40 kDa, wherein said backbone comprises at least 90% alpha-(1,6)-D-glucopyranosidic linkages; whereby the composition is useful for improving the health of a subject.
US Pat. No. 10,167,347

CARBOXYLATE ESTER OF POLYSACCHARIDE

BASF SE, Ludwigshafen (D...

1. A carboxylate ester of polysaccharide, wherein the polysaccharide is esterified with trimellitic anhydride and wherein a degree of substitution of the polysaccharide lies in the range of from 1 to 2.5.
US Pat. No. 10,168,630

TONER FOR DEVELOPING ELECTROSTATIC IMAGES

KONICA MINOLTA, INC., To...

1. A toner for developing electrostatic images, comprising toner particles containing an external additive on surfaces of toner matrix particles,wherein the external additive contains at least a lanthanum-containing titanate compound.
US Pat. No. 10,167,349

CATALYST SYSTEM FOR THE POLYMERIZATION OF OLEFINS

Basell Poliolefine Italia...

1. A catalyst system for olefin polymerization comprising the product obtained by contacting:(a) a solid catalyst component comprising Mg, Ti, a halogen and a 1,2-phenylene aromatic diester;
(b) triethylaluminum; and
(c) an additional ester selected from the group consisting of diethyl pimelate and diethyl suberate;
wherein the molar ratio of 1,2-phenylene aromatic diester to additional ester is 0.1-10.
US Pat. No. 10,167,350

PREPARATION OF POLYOLEFIN

Univation Technologies, L...

1. A polymerization catalyst for forming a polyethylene copolymer, comprising:a plurality of silica particles;
a metallocene catalyst supported on the plurality of silica particles, wherein the metallocene catalyst is bis(n-propylcyclopentadienyl) hafnium (CH3)2, bis(n-propylcyclopentadienyl) hafnium F2, bis(n-propylcyclopentadienyl) hafnium Cl2, or any combinations thereof; and
an activator supported on the plurality of silica particles;wherein the polymerization catalyst has a particle size distribution wherein about 10% of the particles have a size less than about 17 to about 23 micrometers, about 50% of the particles have a size less than about 40 to about 45 micrometers, and about 90% of the particles have a size less than about 72 to about 77 micrometers, and wherein:the polymerization catalyst, having the plurality of silica particles dehydrated at 875° C., produces at a reactor temperature of about 77° C. a polymer that has a melt flow ratio of about 26, wherein the melt flow ratio is a ratio of high load melt index to melt index, wherein the polymer having the melt flow ratio of about 26 is formed from polymerization of ethylene and 1-hexene and has at least 50 weight % ethylene derived units, and is formed at a mole ratio of hydrogen to monomer from greater than about 0.0001 to less than about 0.10; and
the polymerization catalyst, having the plurality of silica particles dehydrated at 875° C., produces at a reactor temperature of about 75° C. a polymer that has a melt flow ratio of about 28, wherein the polymer having the melt flow ratio of about 28 is formed from polymerization of ethylene and 1-hexene, has at least 50 weight % ethylene derived units, and is formed at a mole ratio of hydrogen to monomer from greater than about 0.0001 to less than about 0.10.
US Pat. No. 10,167,352

POLYMERIZATION INITIATING SYSTEM AND METHOD TO PRODUCE HIGHLY REACTIVE OLEFIN FUNCTIONAL POLYMERS

University of Massachuset...

1. A process for the preparation of polybutene having an exo-olefin content of at least 50 mol. % from an impure isobutene or an isobutene-containing monomer feedstock containing from about 5 ppm to about 500 ppm of polar impurities, which process comprises contacting said impure isobutene or isobutene-containing feedstock, with a Lewis acid catalyst complexed with a Lewis base, in a substantially or completely apolar polymerization medium, and initiating polymerization of said isobutene or isobutene-containing feedstock with an initiator, wherein said Lewis acid catalyst is a Lewis acid of the formula R?AlCl2, wherein R? is a hydrocarbyl group; said Lewis base is a dihydrocarbyl ether wherein each hydrocarbyl group is independently selected from hydrocarbyl groups having 1 to 8 carbon atoms and one or both hydrocarbyl groups of the dihydrocarbyl ether are substituted with an electron withdrawing group and the initiator is a compound of the formula RX, wherein X is a halide; R is a hydrocarbyl group capable of forming a stable carbocation, and wherein the carbon linking group R to group X is tertiary, benzylic or allylic; wherein the amount of water in said feedstock is controlled to be between an amount at least equal to the molar amount of polar impurities in said feedstock, and less than 5 mM per liter of feedstock.
US Pat. No. 10,167,353

METHODS FOR INCREASING POLYMER PRODUCTION RATES WITH HALOGENATED HYDROCARBON COMPOUNDS

Chevron Phillips Chemical...

1. A process for producing an ethylene polymer at a target productivity, the process comprising:(a) contacting a metallocene-based catalyst system with ethylene and an optional ?-olefin comonomer in a polymerization reactor system under polymerization conditions; and
(b) controlling an amount of a halogenated hydrocarbon compound introduced into the polymerization reactor system to produce the ethylene polymer at the target productivity;
wherein the metallocene-based catalyst system comprises at least one metallocene compound.
US Pat. No. 10,167,356

FLUORINATED POLYMERS COMPRISING PHOSPHONIC MOIETIES

3M Innovative Properties ...

1. A polymer derived from(a) a fluorinated monomer comprising at least one of
(i) CnF(2n+1)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8, z is an integer selected from 1 to 20, and R is H or CH3; and
(ii) CnF(2n+1)SO2(NR?)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8; z is an integer selected from 3 to 20, and R is H or CH3 and R? is H or C1-C8 alkyl group, wherein the fluorinated monomer is selected from a group consisting of CF3CF2CF2CH2—O—C(?O)C(CH3)?CH2; and C8F17CH2CH2OC(?O)CH?CH2” after “alkyl group”; and
(b) a monomer comprising a phosphonic moiety, wherein the phosphonic moiety is selected from a group consisting of: —CH2?CHPO3H2, CH2?CHCH2PO3H2, and CH2?CHC(?O)O(CH2)2PO3H2.
US Pat. No. 10,167,870

CAN FOR MAGNETICALLY COUPLED PUMPS AND PRODUCTION PROCESS

1. A method for manufacturing a separating can (1), said method comprising the steps of:forming a flange part (4) of the can (1);
forming a bottom (2) of the can (1);
forming a side wall (3) arrangeable in a gap between a driver and a rotor of a magnetically coupled pump in a mounted condition of the can at least partially from a material comprising a nickel constituent, with the side wall (3) being brought by a reshaping step into a target geometry, said side wall having a reshaping degree of at least 10 percent, said side wall consisting at least partially of a material containing a nickel constituent, wherein the material is a nickel-chromium-iron alloy material in a solution annealed condition comprising between 50 and 55 percent by weight of nickel, between 17 and 21 percent by weight of chromium, between 10 and 25 percent by weight of iron, and between 0.5 and 10 percent by weight of niobium; further wherein said material has a deformation-free hardenability property; and
performing a hardening of said can after reshaping by a heat treatment; wherein said reshaping is a cold forming procedure and precipitation hardening is performed after cold forming.
US Pat. No. 10,167,359

RADIATION CURING COATING COMPOSITION

PERSTORP AB, Perstorp (S...

1. A coating composition characterised in, that said coating composition is a UV-curing coating composition comprising:(a) 40-70% by weight of at least one urethane (meth)acrylate being a product of a reaction between at least one polycaprolactone polyol (a1) and at least one adduct (a2), said adduct (a2) being a product of a reaction between at least one polyisocyanate (a3) and at least one hydroxyalkyl (meth)acrylate (a4), and said polycaprolactone polyol (a1) being a product of a reaction between at least one polyalkoxylated polyol (a5) and at least one caprolactone monomer (a6),
(b) 20-50% by weight of at least one reactive diluent having at least one olefinic carbon-carbon double bond, and
(c) 0.5-10% by weight of at least one photoinitiator.
US Pat. No. 10,165,823

DAMPING ELEMENT IN SHOE SOLES

BASF SE, Ludwigshafen (D...

1. A process for producing a shoe sole, the shoe sole comprising a hybrid material which comprises a polyurethane foam as a matrix material and an inlay component of expanded particles of a thermoplastic polyurethane;wherein the shoe sole does not comprise foamed particles of thermoplastic polyurethane in a region of at least 0.2 cm from an exterior edge of the shoe sole;
the process comprising:
preparing an inlay form by joining the expanded particles of a thermoplastic polyurethane in an amount and size of the desired inlay by placing them into a mould of the desired inlay size and joining them within the mould to obtain a prepared inlay form or by joining them in larger amounts to form large aggregates or sheets which are then cut to inlays of the desired size to obtain a prepared inlay form;
preparing the shoe sole by placing the prepared inlay form in a shoe sole mold such that an edge of the inlay form is 0.2 cm or more from an edge of the shoe sole mold;
embedding the inlay form within a reaction mixture in the shoe sole mold; and
reacting the reaction mixture to form the matrix in the shoe sole mold; obtain the shoe sole, and
removing the matrix with embedded inlay from the mold to obtain the shoe sole;
wherein the expanded particles of the inlay component are bonded with adhesives or with thermal adhesive bonding, and the reaction mixture comprises: a polyisocyanate; a compound having a hydrogen atom reactive toward isocyanate, and optionally at least one of a chain extender, a crosslinking agent, a catalyst, a blowing agent, and a further additive.
US Pat. No. 10,167,360

PROCESS TO PRODUCE POLYOLEFIN IONOMERS AND IONOMERS PRODUCED THEREBY

Dow Global Technologies L...

1. A process to produce an ionomer comprising:reacting alkyl-cis-cyclooctene and cis-cyclooctene in a mole ratio from 1:0.05 to 0.05:1, in the presence of a difunctional acid chain transfer agent under ring opening metathesis polymerization conditions to form an unsaturated polyolefin reactive telechelic pre-polymer;
hydrogenating the unsaturated polyolefin reactive telechelic pre-polymer to produce a hydrogenated polyolefin reactive telechelic pre-polymer;
reacting the hydrogenated polyolefin reactive telechelic pre-polymer with at least one compound according to the formula aMx+b(R)y, wherein M is a metal, x is a charge of M, R is an alkyl, aryl, oxide, or fatty acid, y is a charge of R, a and b are integers of at least 1, and ax+by=0, to form an ionomer.
US Pat. No. 10,167,361

PRODUCTION OF AROMATICS AND C2+OLEFINS

ExxonMobil Chemical Paten...

1. A process for producing aromatics and C2+ olefins, the process comprising:(a) providing a feed comprising syngas;
(b) reacting at least a portion of the syngas to produce an alcohol-containing mixture comprising C2+ alcohols and ?2 wt. % of methanol, wherein the C2+ alcohols include at least ethanol and propanol and wherein the alcohol-containing mixture comprises ?15 wt. % of ethanol, the weight percentages being based on the weight of the alcohol-containing mixture;
(c) separating a first stream and a second stream from the alcohol-containing mixture, wherein (i) the first stream comprises ?90.0 wt. % of the alcohol-containing mixture's methanol, based on the weight of the alcohol-containing mixture's methanol, (ii) the second stream comprises ?90.0 wt. % of the alcohol-containing mixture's C2+ alcohols, based on the weight of the alcohol-containing mixture's C2+ alcohols, and (iii) the second stream has a propanol:ethanol weight ratio in the range of from 0.1 to 0.5;
(d) reacting at least part of the first stream's methanol to produce a first hydrocarbon and a first oxygenate, the first hydrocarbon comprising ?25.0 wt. % of aromatics, ?1.0 wt. % of propylene, and ?50.0 wt. % of saturated hydrocarbons, the weight percentages being based on the weight of the first hydrocarbon; and
(e) reacting at least part of the second stream's C2+ alcohols to produce a second product comprising a second hydrocarbon and a second oxygenate, wherein (i) the second hydrocarbon comprises C2+ olefins, (ii) the second product comprises ?20.0 wt. % ethylene, based on the weight of the second product, (iii) the second hydrocarbon has a propylene: ethylene ratio in the range of from 0.30 to 0.40, and (iv) the reacting of the at least part of the second stream's C2+ alcohol comprises an oxygenate to olefin reaction.
US Pat. No. 10,167,364

PROCESS FOR PREPARING POLYCARBONATES BY TRANSESTERIFYING DITHIOCARBONATES OR SELENIUM ANALOGUES THEREOF WITH BISPHENOLS

COVESTRO DEUTSCHLAND AG, ...

1. A process for preparing polycarbonates, comprising reacting bisphenols with a transesterifying reagent in the presence of a catalyst, wherein the transesterifying reagent comprises a compound of the general formula (I):R—X—C(O)—X?—R?  (I)
wherein
X and X? are each independently S or Se, and
R and R? are each independently alkyl or aryl or
R and R? together are an alkylene chain.
US Pat. No. 10,167,366

POLYSILOCARB MATERIALS, METHODS AND USES

Melior Innovations, Inc.,...

1. A non-sintered end product comprising a polysilocarb formulation, wherein the end product comprises an SiOxCy moiety, where x?1, y?1, and x+y=4, the end product selected from the group consisting of fibers, proppants, silane coated proppants, silane and antistatic coated proppants, blast shield, a ballistic composite, structural member, trailer, mobile building, shipping container, friction member, grinding device, armored vehicle, body armor, insulation, paint, fire resistant coatings, counter tops, exhaust systems, tubular structures, wiring insulation, pipe insulation, pipe linings, concrete, and vapor barrier; and, the end product comprises about 20 weight % to about 35 weight % carbon; wherein about 55 weight % to about 80 weight % of the carbon is free carbon.
US Pat. No. 10,167,367

POLYCARBONATE BASED PI-PI STABILIZED NANO-OBJECTS AND HYDROGELS

International Business Ma...

2. An amphiphilic block copolymer comprising:a poly(ethylene glycol) (PEG) block;
a first hydrophobic polycarbonate (PC) block bonded to the PEG block, the first hydrophobic PC block including pendant aryl substituents;
a second hydrophobic PC block bonded to the first hydrophobic PC block, the second hydrophobic PC block including pendant fluoroaryl substituents;
a third hydrophobic PC block bonded to the PEG block, the third hydrophobic PC block including the pendant aryl substituents; and
a fourth hydrophobic PC block bonded to the third hydrophobic PC block, the fourth hydrophobic PC block including the pendant fluoroaryl substituents.
US Pat. No. 10,166,088

UNIFIED THREE DIMENSIONAL VIRTUAL CRANIOFACIAL AND DENTITION MODEL AND USES THEREOF

Ora Metrix, Inc., Richar...

1. A method of registering an upper arch and a lower arch of a patient, with accompanying teeth with or without roots, with respect to jaw bones or facial tissue structure, comprising the steps of:capturing a three dimensional volumetric scan of a craniofacial complex and a dentofacial complex of the patient;
defining reference planes; and
registering (1) the three dimensional volumetric scan of the dentofacial complex with accompanying roots and (2) the patient's facial structure to the defined reference planes.
US Pat. No. 10,167,369

LIGHTFAST POLYURETHANE PREPREGS AND FIBER COMPOSITE ELEMENTS PRODUCED THEREFROM

Covestro Deutschland AG, ...

1. A prepreg consisting of a fiber layer saturated with polyurethane (matrix material) that has not been fully hardened and that has an NCO value of from 3% by weight to 17% by weight (DIN EN ISO 14896:2009-07-method A: method A=NCO value determined by titration), and that has a Tg-value below 40° C. (glass transition temperature Tg measured in accordance with DIN EN ISO 53765-A-20), wherein the polyurethane is a reaction product of a reaction mixture of:an isocyanate component consisting of:
A) one or more organic isocyanates selected from the group consisting of: unblocked aliphatic or cycloaliphatic di- and polyisocyanates, isocyanurates of unblocked aliphatic or cycloaliphatic di- and polyisocyanates, and combinations of any thereof;
and a polyol formulation consisting of:
B) a polyol component made of one or more polyols with a number-average OH number of from 30 to 1000 mg KOH/g, with a number-average functionality of from 1.9 to 2.5;
C) one or more dianhydrohexitols;
D) one or more latent catalysts which are catalytically active at temperatures of from 50° to 100° C.; and
E) optionally auxiliaries and/or additives, wherein component E) excludes polyepoxides,
wherein the initial viscosity directly measured after mixing of the reaction mixture at 40° C. is from 2300 to 3200 mPas (measured in accordance with DIN EN ISO 53019), and the ratio of the number of the NCO groups in component A) to the number of the OH groups in components B) and C) is from 1.3:1 to 10:1.
US Pat. No. 10,167,371

MEDICAL DEVICES HAVING ACTIVATED SURFACES

Covidien LP, Mansfield, ...

1. A polymeric medical device having an acid or base-treated surface that is functionalized with one or more click reactive members to provide an activated surface on the polymeric medical device.
US Pat. No. 10,167,627

BUILDING ASSEMBLY INCLUDING A WEATHER RESISTANT BARRIER, A SHEET FOR USE AS A WEATHER RESISTANT BARRIER, A LIQUID COATING COMPOSITION AND METHODS OF MAKING THE FOREGOING

CERTAINTEED CORPORATION, ...

1. A building assembly comprising a building substrate and a weather resistive barrier (WRB), the WRB having a water vapor permeability that decreases with increasing temperature in a temperature range from 5° C. to 60° C. at 75% relative humidity (RH).
US Pat. No. 10,170,704

ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY INCLUDING THE SAME

SAMSUNG DISPLAY CO., LTD....

1. An organic electroluminescent device, comprising:a first electrode;
a hole transport region on the first electrode;
an emission layer on the hole transport region;
an electron transport region on the emission layer; and
a second electrode on the electron transport region,
wherein:
the electron transport region includes a first electron transport layer on the emission layer, and a second electron transport layer on the first electron transport layer,
an absolute value of difference between a highest occupied molecular orbital (HOMO) energy level of the emission layer and a HOMO energy level of the first electron transport layer is about 0.3 eV to about 1.5 eV,
the first electron transport layer includes a first electron transport material and a first n-type dopant, and
the second electron transport layer includes a second electron transport material and a second n-type dopant.